Articles

The National Comprehensive Cancer Network (NCCN) has added a new value criterion to its clinical practice guidelines in the form of “Evidence Blocks” for the evaluation of treatment options.

Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.

Copenhagen, Denmark—Current follow-up strategy for patients with prostate cancer was found to be the least cost-effective approach in an analysis conducted in Europe.

The treatment of patients with brain metastases involves issues of controlling recurrence, side effects, and costs.

The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).

Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.

Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).

The American Society of Clinical Oncology (ASCO) recently issued its framework to assess the value of cancer treatment options in response to the major challenge of escalating healthcare costs in the United States.